Opinion: Drug pricing is secretive. Fix that first

Health care economist Uwe Reinhardt once described pricing in the health care sector as “chaos behind a veil of secrecy.” That description aptly applies to the opaque U.S. pharmaceutical market. To make health care policy that works, we must lift the secret veil on drug pricing. The administration’s recent proposal to fundamentally change the drug rebate process is one step in that direction.